

Gentris Shanghai



Enabling Genomic Innovation in China

Creating Long Term Value for Biorepository and PGx Testing

Gentris is a leading global provider of pharmacogenomic (PGx) testing and biorepository services for clinical trials. Located in Research Triangle Park, NC, the company is building on over a decade of excellence in genomic medicine to create a new, U.S. FDA-compliant laboratory in Zhangjiang Hi-Tech Park, Shanghai, China. Because clinical biospecimens cannot leave the country, Gentris Shanghai provides pharmaceutical clients with PGx testing and sample storage solutions for all phases of clinical development, including China-specific and integrated global studies. This new facility will be part of a platform to advance personalized medicine and drug development in one of the fastest growing markets.

Gentris Shanghai solves a critical need for U.S. quality PGx testing and clinical sample storage in China as drug developers increasingly conduct large trials that span the globe. China has been a primary focus in recent years due to a rapidly growing economy and tremendous investments in pharmaceutical, biotechnology, and innovation infrastructure. Gentris Shanghai provides the necessary services and expertise to conduct PGx-enabled clinical trials in China and accelerate drug development globally. By working with top Chinese officials, scientific leaders, and industry partners, Gentris Shanghai can also facilitate collaborations with U.S. and E.U. partners to create joint translational research projects that will drive new discoveries and better targeting of drugs for the Chinese patient population.

Creating Long Term Value for Biorepository and PGx Testing

Gentris Shanghai will strategically gate in key services in order to meet client demand and ensure a seamless business launch. Biorepository services provide the following offerings:

- Sample management and tracking
- Nucleic acid extraction & purification
- Clinical sample storage

Gentris USA will transfer methods to Gentris Shanghai and coordinate between the U.S. and Chinese sites to provide seamless, high-quality, global PGx solutions for all phases of clinical trials.

Goals for Gentris Shanghai

- ▶ Take advantage of existing collaborations in China to replicate Gentris USA model in China, e.g., U.S. quality standards, science-driven solutions
- ▶ Provide training and education opportunities, e.g., regulatory standards and applying PGx testing
- ▶ Build relationships with Chinese government, academic, and industry organizations to develop collaborations with pharma companies in the USA, Europe, and Japan
- ▶ Expand service offerings, e.g., clinical services

Building Research Partnerships

Gentris Shanghai is working closely with government organizations, medical researchers, and hospitals to create translational research, education, and training collaborations focused on pharmacogenomics and biobanking that will drive innovation in drug development and patient care. For example, Gentris, the Shanghai Institutes of Preventative Medicine, and an independent research institute are conducting a study to collect biospecimens from tuberculosis patients in China and utilizing metabolomics, pharmacogenomics, and transcriptomics to evaluate drug-induced liver injury and potential biomarkers.

By working with Gentris and its collaborators, industry sponsors can gain access to unique clinical samples, patient populations, and new technology in China. Opportunities exist to create novel research projects in:

- Oncology
- Infectious disease
- Metabolic disease
- Pharmacoepidemiology

Sponsors will be intimately involved in the development and design of research collaborations to ensure project milestones and endpoints align with their strategic objectives. Ultimately, these partnerships can lead to new innovations and genomic biomarkers that will drive value in the global marketplace.

Gentris Shanghai at a Glance

- Business license obtained in May 2012
- Collaborative research agreements with Chinese experts
- Biorepository launch in 2013
- Genotyping launch in 2014
- 2,800 sq. ft. facility
- CLIA, GLP compliant
- Located in Zhangjiang Hi-Tech Park Incubator

For more information, contact:

Gentris, LLC | A CGI Company

133 Southcenter Ct., Suite 400

Morrisville, NC 27560

(919) 465-0100

www.gentris.com

Gentris[®]
A CGI COMPANY